IIL
Innate Immuno
- Short interest
- 0.19%
- +0.11 pp 30d
- as of 27 June 2018
- Reported shorts
- 79K
- Shares on issue
- 41.023M
Innate Immuno (IIL) financials
Results, ratios and statements
Fundamentals
Our data providers hold no financial statements for IIL (last checked 15 Oct 2026). The company's own filings are listed below.
Financial reports
The company's own filings, newest first
- Preliminary Final Report and Annual Report YE 31 March 2026Annual Results29 May 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Apr 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results27 Nov 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Oct 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2025via asx_announcements
- Preliminary Final Report and Annual Report YE 31 March 2025Annual Results30 May 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2025via asx_announcements
- App 4D and Financial Report Half Year ended 30 Sep 2024Half Year Results27 Nov 2024via asx_announcements
Showing 10 of 78 reports